The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 2 open-label study of the efficacy of ABT-199 (GDC-0199) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) harboring 17p deletion.
William G. Wierda
Consultant or Advisory Role - Roche/Genentech
Research Funding - AbbVie; Roche/Genentech
John Francis Seymour
Consultant or Advisory Role - Roche/Genentech
Research Funding - AbbVie; Genentech
Andrew Warwick Roberts
Employment or Leadership Position - Walter and Eliza Hall Institute of Medical Research
Research Funding - AbbVie; Genentech
Soham Puvvada
No relevant relationships to disclose
Matthew Steven Davids
No relevant relationships to disclose
Shekman Wong
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Ming Zhu
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Elisa Cerri
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Rod Humerickhouse
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Stephan Stilgenbauer
Consultant or Advisory Role - AbbVie; Roche/Genentech
Research Funding - AbbVie; Roche